臺灣博碩士論文加值系統

類黃酮已經被研究出許多抗癌活性，包括抗增生、促進細胞凋亡、抗血管新生和細胞週期阻斷。約有30%的乳癌和卵巢癌病人有HER2基因放大或是HER2過表現的現象，且HER2過表現和細胞轉移及抗藥性有關。一系列新穎的黃酮類化合物被用來探討其對癌細胞的抗癌作用。我們發現了Cpd3 (5,7-Dihydroxy-3’,4’-Diaminoflavone)在HER2過表現癌細胞中有明顯的抗癌活性，包括抗增生、抗轉移以及促進細胞凋亡。此外，Cpd3可以增加HER2過表現細胞細胞中的HER2降解。這些結果表明，Cpd3可能是透過降低HER2的表現量以抑制HER2過表現細胞的細胞生長。

Flavonoids have been studied for their anti-tumor properties, including anti-proliferative, proapoptotic, anti-angiogenic and cell cycle arrest activities in several cancer cells. Her2 is amplified and/or overexpressed in about 30% of ovarian and breast cancers and is associated with metastasis and drug resistance. A series of novel flavones were used to explore their anticancer effects on cancer cells. We found a 5,7-Dihydroxy-3’,4’-Diaminoflavone, Cpd3, with significant anti-tumor activities in HER2-overexpressing cancer cells, including anti-proliferative, anti-metastatic, and proapoptotic activities. Moreover, Cpd3 could increase the HER2 degradation in HER2-overexpressing cells. These data suggest that cpd3 suppress the HER2-overexpressing cancer cells growth may via down-regulation of HER2.

謝誌 I
縮寫表 IV
目錄 V
第一章 緒論 1
第一節HER2/neu 1
1-1 HER2/neu的簡介 1
1-2 HER2和癌症間的關係 3
1-3 HER2的訊號路徑 3
1-4 以HER2為目標的治療方式 4
1-4-1單株抗體 (monoclonal antibodies, mAbs) 5
1-4-2 酪胺酸激酶抑制劑 (tyrosine kinase inhibitors) 6
1-4-3 Hsp90 (Heat shock protein 90) 抑制劑 6
第二節 黃酮類化合物 7
2-1黃酮類的簡介 7
2-2黃酮類和癌症的關係 9
研究動機 11
第二章 材料與方法 12
第一節 材料 12
1-1 試劑 (Reagent) 12
1-2 抗體 (Antibody) 13
第二節 方法 13
第三章 結果 21
第一節實驗結果 21
第二節 實驗圖表 25
第四章 討論 32
第五章 參考資料 34
附錄一 42
附錄二 45

Albanell, Joan, et al. "Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4." New Trends in Cancer for the 21st Century. Springer US, 2003. 253-268.

Bazley, L. A., and W. J. Gullick. "The epidermal growth factor receptor family."Endocrine-related cancer 12.Supplement 1 (2005): S17-S27.

Benusiglio, Patrick R. "Focus on ERBB2." (2008): 825-828.

Chan, Richard, et al. "Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development." Development131.22 (2004): 5551-5560.

Chang, Hsueh-Ling, et al. "Protoapigenone, a novel flavonoid, inhibits ovarian cancer cell growth in vitro and in vivo." Cancer letters 267.1 (2008): 85-95.

Chen, C. Y., G. Chen, and W. Y. Chen. "Molecular simulation of HER2/neu degradation by inhibiting HSP90." JOURNAL-CHINESE CHEMICAL SOCIETY TAIPEI 55.2 (2008): 297.

Chen J, Li Z, Chen AY, Ye X, Luo H, Rankin GO, Chen YC. " Inhibitory effect of baicalin and baicalein on ovarian cancer cells." Int J Mol Sci. 2013 Mar 15;14(3):6012-25

Chiang, Chun-Te, Tzong-Der Way, and Jen-Kun Lin. "Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21WAF1/CIP1 expression with rapamycin." Molecular cancer therapeutics 6.7 (2007): 2127-2138.

Cook, N. C., and St Samman. "Flavonoids—chemistry, metabolism, cardioprotective effects, and dietary sources." The Journal of Nutritional Biochemistry 7.2 (1996): 66-76.

Coussens, Lisa, et al. "Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene." Science230.4730 (1985): 1132-1139.

Di Fiore, Pier Paolo, et al. "erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells." Science 237.4811 (1987): 178-182.

English, Jessie M., and Melanie H. Cobb. "Pharmacological inhibitors of MAPK pathways." Trends in Pharmacological Sciences 23.1 (2002): 40-45.

Grassi, Davide, Giovambattista Desideri, and Claudio Ferri. "Flavonoids: antioxidants against atherosclerosis." Nutrients 2.8 (2010): 889-902.

Guiu, Severine, et al. "Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy." Journal of oncology 2013 (2013).

Herlaar, Ellen, and Zarin Brown. "p38 MAPK signalling cascades in inflammatory disease." Molecular medicine today 5.10 (1999): 439-447.

Hung, Chao-Ming, et al. "Osthole suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition via repression of the c-Met/Akt/mTOR pathway in human breast cancer cells." Journal of agricultural and food chemistry 59.17 (2011): 9683-9690.

Lopez-Lazaro, Miguel. "Distribution and biological activities of the flavonoid luteolin." Mini reviews in medicinal chemistry 9.1 (2009): 31-59.

Le Marchand, Loic. "Cancer preventive effects of flavonoids—a review."Biomedicine & pharmacotherapy 56.6 (2002): 296-301.

Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, Feng X, Seewaldt VL, Muller WJ, Sahin A, Hung MC,Yu D." 14-3-3zeta Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition." Cancer Cell. 2009 Sep 8;16(3):195-207

Olayioye, Monilola A. "Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members." Breast Cancer Res 3.6 (2001): 385-389.

Mendelsohn, John, and Jose Baselga. "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer." Journal of clinical oncology 21.14 (2003): 2787-2799.

Murphy, Conleth G., and Shanu Modi. "HER2 breast cancer therapies: a review." Biologics: targets & therapy 3 (2009): 289.

Osaki, M., M. and Oshimura, and H. Ito. "PI3K-Akt pathway: its functions and alterations in human cancer." Apoptosis 9.6 (2004): 667-676.

Prasad, Sahdeo, et al. "Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer." Planta medica 76.11 (2010): 1044-1063.

Prochazkova, D., I. Boušova, and N. Wilhelmova. "Antioxidant and prooxidant properties of flavonoids." Fitoterapia 82.4 (2011): 513-523.

Ren, Wenying, et al. "Flavonoids: promising anticancer agents." Medicinal research reviews 23.4 (2003): 519-534.

Schechter, Alan L., et al. "The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor." Science 229.4717 (1985): 976-978.

Seelinger, Gunter, et al. "Anti-carcinogenic effects of the flavonoid luteolin."Molecules 13.10 (2008): 2628-2651.

Seger, Rony, and Edwin G. Krebs. "The MAPK signaling cascade." The FASEB journal 9.9 (1995): 726-735.

Semba, Kentaro, et al. "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma." Proceedings of the National Academy of Sciences 82.19 (1985): 6497-6501.

Seo, Hye-Sook, et al. "Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFκB signaling in HER2-overexpressing breast cancer cells." Molecular and cellular biochemistry 366.1-2 (2012): 319-334.

Soga, Shiro, Shiro Akinaga, and Yukimasa Shiotsu. "Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development." Current pharmaceutical design 19.3 (2013): 366-376.

Solit, David B., et al. "17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts." Clinical cancer research 8.5 (2002): 986-993.

Stancovski, Ilana, et al. "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth." Proceedings of the National Academy of Sciences 88.19 (1991): 8691-8695.

Way, Tzong-Der, Ming-Ching Kao, and Jen-Kun Lin. "Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway." Journal of Biological Chemistry 279.6 (2004): 4479-4489.

Yu, Dihua, and Mien-Chie Hung. "Overexpression of ErbB2 in cancer and ErbB2-targeting strategies." Oncogene 19.53 (2000): 6115.

Yu, Dihua, and Mien-Chie Hung. "The erbB2 gene as a cancer therapeutic target and the tumor-and metastasis-suppressing function of E1A." Cancer and Metastasis Reviews 17.2 (1998): 195-202.

Zhang, Lisha, et al. "Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin." Cancer research 55.17 (1995): 3890-3896.

Zhang, Lisha, et al. "Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties." Oncogene 16.22 (1998): 2855-2863.

Zhu, Yi, et al. "Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells." Cancer cell international 13.1 (2013): 54.

方冠勳碩士論文，2009，淡江大學，台北，中華民國。